Low incidence of peripheral edema.
Low hepatotoxicity.
Authentic
Guarantee
Fast Delivery
Privacy Carmatinib is a targeted therapy for non-small cell lung cancer with MET exon 14 skipping mutations. For patients using this drug, the most crucial co···【More】
Update: 13 Mar,2026Source: BigbearViews: 114
Carmatinib (Tabrecta) is a highly selective MET receptor tyrosine kinase inhibitor that specifically inhibits the phosphorylation of MET receptors and···【More】
Update: 13 Mar,2026Source: BigbearViews: 104
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos



